481 related articles for article (PubMed ID: 31110329)
1. Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features.
Karamitopoulou E
Br J Cancer; 2019 Jul; 121(1):5-14. PubMed ID: 31110329
[TBL] [Abstract][Full Text] [Related]
2. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
3. New insights into the role of EMT in tumor immune escape.
Terry S; Savagner P; Ortiz-Cuaran S; Mahjoubi L; Saintigny P; Thiery JP; Chouaib S
Mol Oncol; 2017 Jul; 11(7):824-846. PubMed ID: 28614624
[TBL] [Abstract][Full Text] [Related]
4. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
Wartenberg M; Zlobec I; Perren A; Koelzer VH; Gloor B; Lugli A; Karamitopoulou E
Oncotarget; 2015 Feb; 6(6):4190-201. PubMed ID: 25669968
[TBL] [Abstract][Full Text] [Related]
5. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of pancreatic cancer.
Sunami Y; Kleeff J
Prog Mol Biol Transl Sci; 2019; 164():189-216. PubMed ID: 31383405
[TBL] [Abstract][Full Text] [Related]
7. Clinical Scenarios Emerging from Combined Immunophenotypic, Molecular and Morphologic Analysis of Pancreatic Cancer: The Good, the Bad and the Ugly Scenario.
Karamitopoulou E; Gloor B
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31295960
[TBL] [Abstract][Full Text] [Related]
8. Multimodal Molecular Imaging of the Tumour Microenvironment.
Foray C; Barca C; Backhaus P; Schelhaas S; Winkeler A; Viel T; Schäfers M; Grauer O; Jacobs AH; Zinnhardt B
Adv Exp Med Biol; 2020; 1225():71-87. PubMed ID: 32030648
[TBL] [Abstract][Full Text] [Related]
9. T-cell programming in pancreatic adenocarcinoma: a review.
Seo YD; Pillarisetty VG
Cancer Gene Ther; 2017 Mar; 24(3):106-113. PubMed ID: 27910859
[TBL] [Abstract][Full Text] [Related]
10. The impact of cancer-associated fibroblasts on major hallmarks of pancreatic cancer.
Sun Q; Zhang B; Hu Q; Qin Y; Xu W; Liu W; Yu X; Xu J
Theranostics; 2018; 8(18):5072-5087. PubMed ID: 30429887
[TBL] [Abstract][Full Text] [Related]
11. Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse A; Bauer CA; Öhlund D; Lauth M; Buchholz M; Michl P; Tuveson DA; Gress TM
Gut; 2019 Jan; 68(1):159-171. PubMed ID: 30177543
[TBL] [Abstract][Full Text] [Related]
12. Understanding the immune landscape and tumor microenvironment of pancreatic cancer to improve immunotherapy.
Torphy RJ; Schulick RD; Zhu Y
Mol Carcinog; 2020 Jul; 59(7):775-782. PubMed ID: 32166821
[TBL] [Abstract][Full Text] [Related]
13. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
14. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
15. Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.
Kinoshita T; Kudo-Saito C; Muramatsu R; Fujita T; Saito M; Nagumo H; Sakurai T; Noji S; Takahata E; Yaguchi T; Tsukamoto N; Hayashi Y; Kaseda K; Kamiyama I; Ohtsuka T; Tomizawa K; Shimoji M; Mitsudomi T; Asamura H; Kawakami Y
Eur J Cancer; 2017 Nov; 86():15-27. PubMed ID: 28950145
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
[TBL] [Abstract][Full Text] [Related]
17. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
[TBL] [Abstract][Full Text] [Related]
18. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
19. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
20. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
